Genmab A/S
BISPECIFIC ANTIBODIES AGAINST CD3 AND CD20
Last updated:
Abstract:
Bispecific antibodies directed to CD3 and CD20 and uses of such bispecific antibodies, in particular use thereof in the treatment of diseases in which specific targeting and T cell-mediated killing of cells that express CD20 is desired.
Status:
Application
Type:
Utility
Filling date:
4 Dec 2019
Issue date:
25 Jun 2020